References
- Krober A, Seiler T, Benner A, et al VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410–1416.
- Dohner H, Stilgenbauer S, Benner A, et al Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916.
- Stilgenbauer S, Sander S, Bullinger L, et al Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007;92:1242–1245.
- Byrd JC, Gribben JG, Peterson BL, et al Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006;24:437–443.
- Catovsky D. The changing face of chronic lymphocytic leukemia. Leuk Lymphoma 2007;48:2283–2284.
- Dohner H, Stilgenbauer S, James MR, et al 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516–2522.
- Zenz T, Dohner H, Stilgenbauer S. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007;20:439–453.
- Krober A, Bloehdorn J, Hafner S, et al Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969–975.
- Grever MR, Lucas DM, Dewald GW, et al Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25:799–804.
- Shanafelt TD, Witzig TE, Fink SR, et al Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24:4634–4641.
- Dohner H, Fischer K, Bentz M, et al p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580–1589.
- Byrd JC, Smith L, Hackbarth ML, et al Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003;63:36–38.
- Lozanski G, Heerema NA, Flinn IW, et al Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278–3281.
- Stilgenbauer S, Zenz T, Winkler D, et al Subcutaneous alemtuzumab (Campath) in fludarabine-refractory CLL: final results of the CLL2H trial of the GCLLSG and comprehensive analysis of prognostic markers. Blood 2008;112 (Supp.11): Abstract 329.
- Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140:36–45.
- Chanan-Khan A, Miller KC, Musial L, et al Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343–5349.
- Cheson BD, Bennett JM, Grever M, et al National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
- Ferrajoli A, Lee BN, Schlette EJ, et al Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–5297.